Mundipharma, a global pharma network, has announced that laboratory testing at the Duke-NUS Medical School in Singapore confirmed the effectiveness of its BETADINE antiseptic products against the SARS-CoV-2 that causes COVID-19 disease, it was reported on Thursday.
Testing indicated that the product's in-vitro virucidal activity kills 99.99% of the virus in 30 seconds.
Another Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center at the University of Malaya, Malaysia, also indicated strong in-vitro virucidal activity, with the tested product BETADINE Gargle and Mouthwash (1.0-% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds. The BETADINE antiseptic range includes Povidone-iodine.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients